Following on from information provided to NICE by the company in September 2017 the appraisal of Mastocytosis (systemic) - masitinib [ID781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 781

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Timeline

Key events during the development of the guidance:

Date Update
21 December 2022 Discontinued. Following on from information provided to NICE by the company in September 2017 the appraisal of Mastocytosis (systemic) - masitinib [ID781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
18 September 2017 Suspended. The Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for masitinib for treating systematic mastocytosis. Consequently the first appraisal committee discussion of this topic, has been cancelled. We will continue to monitor any developments and will update interested parties if the situation changes.
12 February 2016 Following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late August 2016 when. The deadline for submissions is expected in approximately late October 2016.
27 November 2015 Draft scope documents
04 November 2015 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual